Leerink Partners analyst Daina Graybosch maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $104.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Daina Graybosch has given her Buy rating due to a combination of factors that highlight Gilead Sciences’ strong performance and potential growth. The company’s recent quarterly results were robust, primarily driven by the success of its HIV franchise, which showed impressive revenue figures despite facing some short-term challenges. This solid performance reinforces the optimistic outlook for Gilead’s business, with the HIV segment expected to continue its growth trajectory.
Additionally, Graybosch sees significant growth opportunities in Gilead’s oncology pipeline and other therapeutic areas. Notably, the anticipated FDA approval and subsequent launch of lenacapavir for PrEP in the near future are expected to tap into a highly receptive market. Furthermore, the positive outlook for Gilead’s oncology endeavors, including the promising developments for Trodelvy in breast cancer treatments and advancements in CAR-T therapies, supports the Buy rating. These elements combined with improved operating margins contribute to an increased price target, reflecting confidence in Gilead’s future financial performance.
Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, BioNTech SE, and Affimed. According to TipRanks, Graybosch has an average return of -15.8% and a 30.18% success rate on recommended stocks.